NCT06156683 - Kesimpta Pregnancy and Infant Safety Study Using Real World Data | Biotech Hunter

Enrollment

1,500

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

February 1, 2028

Study Completion Date

February 1, 2028

Conditions

Multiple Sclerosis

Interventions

OTHER

Multiple sclerosis disease modifying drug

There is no treatment allocation. Women with multiple sclerosis with a recorded pregnancy outcome during the inclusion period will be recruited.

Trial Locations (1)

RECRUITING

Novartis Investigative Site, Basel